Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03251092 · ClinicalTrials.gov registry record · Phase 1
Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis
A Phase 1 study of Cystic Fibrosis - Complete and Healthy Volunteer - Complete, sponsored by Proteostasis Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 179
- Enrollment target
- 20
- Study locations
NCT03251092 is a Phase 1 study of Cystic Fibrosis - Complete and Healthy Volunteer - Complete that has completed, run by Proteostasis Therapeutics. The registered enrollment target is 179 participants. The trial reports 20 study locations across 18 states.
The verdict
NCT03251092, a Phase 1 study of Cystic Fibrosis - Complete and Healthy Volunteer - Complete, has completed, sponsored by Proteostasis Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 179 participants
- Enrollment target
- 20
- Study locations
Study Summary
Part 1 of this trial will enroll healthy volunteers into a single ascending dose (SAD), multiple ascending dose (MAD), and Food Effect (FE) treatment groups. The SAD treatment group is comprised of at least 3 ascending dose level cohorts where healthy adult subjects will be randomized to receive a single dose of either PTI-808 or placebo and will be followed for 7 days post dose. A safety review committee (SRC) will convene after the completion of each cohort to evaluate safety and pharmacokinetic (PK) data. Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 ascending dose level cohorts where subjects will be randomized to receive either PTI-808 or placebo daily for 7 days and will be followed for 7 days after receiving the last dose. Also following the conclusion of the respective SAD level dose groups, healthy adult subjects will participate in the FE treatment group. Part 2 of this will enroll healthy volunteers to assess the safety, tolerability, and PK of PTI 808 co administered with PTI 801 and PTI 428 to HVs with daily dosing for 7 consecutive days. Part 3 will enroll adult subjects with cystic fibrosis (CF) into a MAD treatment group consisting of 2 cohorts. Subjects will receive PTI-808 co-administered with PTI-801 and PTI-428. PTI-808 will be administered daily for 7 consecutive days followed by PTI-808 + PTI-801 + PTI-428 administered daily for 14 consecutive days. Part 4 will enroll adult subjects with cystic fibrosis (CF) into 28-day cohorts. Subjects will receive PTI-808 co-administered with PTI-801 with or without PTI-428 versus matching placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PTI-808
- DRUG PTI-428
- DRUG PTI-801
Study Locations (20)
Massachusetts
- Massachusetts General Hospital - Boston
- Boston Children's Hospital - Boston
Michigan
- Michigan Medicine, University of Michigan - Ann Arbor
- Harper University Hospital - Detroit
Arizona
- Banner University of Arizona Medical Center - Tucson
California
- Stanford University Medical Center - Stanford
Colorado
- National Jewish Health - Denver
Florida
- Central Florida Pulmonary Group - Altamonte Springs
Georgia
- Emory Children's Center - Atlanta
Illinois
- Northwestern Memorial Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2017-07-17 |
| Est. Completion | 2019-12-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03251092
The ClinicalTrials.gov registry entry for NCT03251092 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 179 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Proteostasis Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cystic Fibrosis - Complete appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT03251092 reports 20 study locations spanning 18 distinct geographic areas - top geographies include Massachusetts, Michigan, Arizona.
Frequently Asked Questions
What is clinical trial NCT03251092 about?
NCT03251092 is a clinical study titled "Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis". Part 1 of this trial will enroll healthy volunteers into a single ascending dose (SAD), multiple ascending dose (MAD), and Food Effect (FE) treatment groups. The SAD treatment group is comprised of at least 3 ascending dose level cohorts where healthy adult subjects will be randomized to receive a ...
What is the current status of trial NCT03251092?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 179 participants. The study started on 2017-07-17. Estimated completion is 2019-12-23.
What conditions does trial NCT03251092 study?
This clinical trial studies the following conditions: Cystic Fibrosis - Complete, Healthy Volunteer - Complete.
What interventions are being tested in trial NCT03251092?
The interventions under investigation include: Placebo (DRUG), PTI-808 (DRUG), PTI-428 (DRUG), PTI-801 (DRUG).
Who is sponsoring clinical trial NCT03251092?
This trial is sponsored by Proteostasis Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03251092 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis - Complete
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.